SM
MRNA icon

SG3 Management’s Moderna MRNA Stock Holding History

SG3 Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,800
Closed -$503K – 115
2022
Q4 		$503K Hold
2,800
– – 0.07% 116
2022
Q3 		$331K Sell
2,800
-25,000
-90% -$3.79M 0.04% 167
2022
Q2 		$3.97M Sell
27,800
-36,000
-56% -$5.15M 0.47% 45
2022
Q1 		$11M Buy
63,800
+36,000
+129% +$6.06M 0.31% 74
2021
Q4 		$7.06M Buy
27,800
+25,700
+1,224% +$7.51M 0.14% 128
2021
Q3 		$808K Sell
2,100
-77,900
-97% -$28.7M 0.02% 501
2021
Q2 		$18.8M Sell
80,000
-25,000
-24% -$4.47M 0.67% 25
2021
Q1 		$13.8M Sell
105,000
-140,000
-57% -$20.3M 0.34% 60
2020
Q4 		$25.6M Buy
245,000
+82,500
+51% +$8.35M 0.49% 33
2020
Q3 		$11.5M Buy
162,500
+140,300
+632% +$9.78M 0.43% 55
2020
Q2 		$1.43M Sell
22,200
-97,800
-82% -$5.36M 0.1% 237
2020
Q1 		$3.59M Buy
+120,000
New +$2.76M 0.48% 39

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SG3 Management's MRNA Position: Q1 2022 in Review

SG3 Management sold out of Moderna (MRNA) in Q1 2022, closing a stake of 19,000 shares — an estimated $3.2M sold.

SG3 Management first reported a position in MRNA in Q2 2020 and held it in 4 quarters. The position peaked at $20.2M in Q3 2021. 1,007 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • SG3 Management reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • SG3 Management sold 19,000 Moderna shares in Q1 2022, an estimated $3.2M.
  • SG3 Management first reported a position in Moderna in Q2 2020 and held it in 4 quarters.
  • SG3 Management's Moderna position peaked at $20.2M in Q3 2021.
  • 1,007 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.